SYNVISC ONE®

Synvisc-One:

• Is a temporary replacement and supplement for synovial fluid.
• Is beneficial for patients in all stages of knee pathology.
• Is most effective in patients who are actively and regularly using the affected knee.
• Achieves its therapeutic effect through viscosupplementation, a process whereby the physiological and rheological states of the arthritic knee tissues are restored.
• Viscosupplementation with Synvisc-One is a treatment to decrease pain and discomfort, allowing more extensive movement of the knee. In vitro studies have shown that hylan G-F 20 protects cartilage cells against certain physical and chemical damage.
• Synvisc-One is only intended for intra-articular use by a physician to treat pain associated with osteoarthritis of the knee.

• Hylan G-F 20 (Synvisc-One) is indicated:
• For the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics.
• For the treatment to decrease pain & discomfort allowing more extensive movement of the Knee.
• The safety and efficacy of Synvisc-One for conditions other than osteoarthritis has not been established.
• The safety and effectiveness of the use of Synvisc-One concomitantly with other intra-articular injectables has not been established.

Synvisc-One (hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing hylans. Hylans are derivatives of hyaluronan (sodium salt of hyaluronic acid) and consist of repeating disaccharide units of N-acetylglucosamine and sodium glucuronate. Hylan A has an average molecular weight of approximately 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains hylan A and hylan B (8.0 mg ± 2.0 mg per ml) in buffered physiological sodium chloride solution (pH 7.2 ± 0.3).

Contraindications

• If venous or lymphatic stasis is present, Synvisc-One should not be injected into the knee.
• Synvisc-One should not be used in infected or severely inflamed knees or in patients having skin diseases or infections in the area of the injection site.

After-care

• Avoid activities that put excessive strain on your knee, such as jogging, lifting, or prolonged standing for 48 hours following the injection. Please consult your doctor regarding the appropriate time to resume such activities.
• If you have any mild pain or swelling at the injection site, apply an ice pack on your knee as recommended by your doctor.
• The most common side effects seen with the SYNVISC® family are pain, swelling, heat, redness, and fluid buildup around the knee. Please consult your doctor if you have concerns, if your symptoms do not go away, and/or if you have other side effects.